3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
4
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Liver Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
26
Nivolumab
21
pembrolizumab
15
Bevacizumab
14
lenvatinib
12
atezolizumab
9
Cyclophosphamide
9
Ipilimumab
8
durvalumab
6
camrelizumab
5
apatinib
5
Specimen Handling
5
Radiosurgery
5
tislelizumab
4
fludarabine
4
Immunotherapy, Adoptive
4
Fluorouracil
4
Doxorubicin
4
tremelimumab
3
toripalimab
3
sintilimab
3
regorafenib
3
cabozantinib
3
X-Rays
3
Magnetic Resonance Spectroscopy
3
Injections
3
Everolimus
3
Ethiodized Oil
3
Erlotinib Hydrochloride
3
tepotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Hepatocellular
×
Yttrium-90
×
Clear all
NCT06725121
2024-12-16
MacroTrans
University Health Network, Toronto
Phase 1/2
Recruiting
48 enrolled